Higher scores were found in the high-risk group, indicating that high-risk ccRCC patients demonstrated a heightened sensitivity to PD-1 and CTLA-4 single-agent and dual-agent combination immunotherapies (Fig. 7J–M). This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.